PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsEtonogestrel
Etonogestrel
Eluryng, Enilloring, Ethinyl Estradiol / Etonogestrel, Haloette, Nexplanon, Nuvaring (etonogestrel) is a small molecule pharmaceutical. Etonogestrel was first approved as Nuvaring on 2001-10-03.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Nexplanon (discontinued: Nexplanon)
Combinations
Eluryng, Enilloring, Ethinyl estradiol; etonogestrel, Haloette, Nuvaring (discontinued: Veraring)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Etonogestrel
Tradename
Company
Number
Date
Products
NEXPLANONOrganonN-021529 RX2011-05-13
1 products, RLD, RS
Show 1 discontinued
Ethinyl estradiol
+
Etonogestrel
Tradename
Company
Number
Date
Products
NUVARINGOrganonN-021187 RX2001-10-03
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
eluryngANDA2024-08-20
enilloringANDA2024-06-24
etonogestrel and ethinyl estradiolANDA2022-09-30
etonogestrel and ethinyl estradiol vaginalANDA2024-07-08
etonogestrel and ethinyl estradiol vaginal ringANDA2024-06-24
etonogestrel/ethinyl estradiolNDA authorized generic2024-06-21
haloetteANDA2024-04-19
nexplanonNew Drug Application2024-12-13
nuvaringNew Drug Application2024-12-13
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
prostatic neoplasms—D011471C61
breast neoplasmsEFO_0003869D001943C50
menorrhagiaEFO_0003945D008595N92.0
primary ovarian insufficiencyEFO_0004266D016649E28.3
hot flashes—D019584—
hypogonadismHP_0000044D007006E23.0
premature menopauseHP_0008209D008594E28.31
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Etonogestrel, Implanon, Organon
97575522030-07-28DPU-1
87220372027-09-28DP
108212772027-05-31DP
88887452026-08-28DP
ATC Codes
G: Genito urinary system and sex hormones
— G03: Sex hormones and modulators of the genital system
— G03A: Hormonal contraceptives for systemic use
— G03AC: Progestogen systemic hormonal contraceptives
— G03AC08: Etonogestrel
HCPCS
Code
Description
J7295
Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each
J7307
Etonogestrel (contraceptive) implant system, including implant and supplies
Clinical
No data
Drug
General
Drug common nameEtonogestrel
INNetonogestrel
Description
Etonogestrel is a medication which is used as a means of birth control for women. It is available as an implant placed under the skin of the upper arm under the brand names Nexplanon and Implanon. It is a progestin that is also used in combination with ethinylestradiol, an estrogen, as a vaginal ring under the brand names NuvaRing and Circlet. Etonogestrel is effective as a means of birth control and lasts at least three or four years with some data showing effectiveness for five years. Following removal, fertility quickly returns.
Classification
Small molecule
Drug classestrogens; progestins
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3C(=C)C[C@@]21CC
Identifiers
PDB—
CAS-ID54048-10-1
RxCUI—
ChEMBL IDCHEMBL1531
ChEBI ID50777
PubChem CID21729469
DrugBankDB00294
UNII ID304GTH6RNH (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Nexplanon – Organon
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Nexplanon – Merck & Co
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Nuvaring – Organon
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Nuvaring – Merck & Co
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Etonogestrel
+
Ethinyl estradiol
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Etonogestrel
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
No data
Safety
Black-box Warning
Black-box warning for: Eluryng, Enilloring, Etonogestrel and ethinyl estradiol, Etonogestrel and ethinyl estradiol vaginal, Etonogestrel and ethinyl estradiol vaginal ring, Etonogestrel/ethinyl estradiol, Haloette, Nuvaring
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use